The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > REGULATORY
REGULATORY
- Gilead’s Sofosbuvir Could Join NHI Price List in May If OK’ed by PAFSC Panel on March 5
February 20, 2015
- MHLW Picks 4 Hospitals Eligible for Special Mixed Care Scheme in Tokyo Economic Zone
February 20, 2015
- Panel OKs Intractable Disease Designation of 43 More Diseases
February 19, 2015
- Japan Generic Share at 55% in September 2014: MHLW
February 19, 2015
- Chuikyo Approves 26 Products Including Takecab, Zelboraf for Listing
February 19, 2015
- Add Risk of Interstitial Pneumonia to Eliquis Package Insert: MHLW
February 18, 2015
- Abe Calls for Shrewd Strategies for Pharmas, Industry Consolidation as Necessary
February 18, 2015
- LDP Pharma Policy Study Group on Alert for 3 Consecutive Years of Drug Price Cuts
February 17, 2015
- MHLW Approves 309 Generic Products Ahead of June Listing; 32 Companies Obtain Approval for Plavix Generics Including AGs
February 17, 2015
- Panel Approves 43 More Diseases as Designated Intractable Diseases
February 17, 2015
- Gilead Told to Improve Biz Practice in Japan over Delayed ADR Reporting
February 16, 2015
- Health Minister to Kick Off Roundtable for Healthcare Policy for 2035 This Month
February 16, 2015
- PAFSC’s Second Committee to Discuss Celgene’s Multiple Myeloma Treatment Pomalidomide on Feb. 26
February 13, 2015
- PMDA Plans Manufacturing Inspections for 2 Regenerative Medicine Products This Year
February 12, 2015
- MHLW Pursuing Quick Approval of Japan-OK’ed Drugs in Emerging Markets
February 10, 2015
- Health Minister Says to Mull Revising Generic Share Target
February 10, 2015
- National Cancer Center Announces Guidelines for Clinical Trial Monitoring and Auditing
February 10, 2015
- Editor’s Pick: Five Healthcare News Headlines for Jan. 26 - Feb. 8
February 9, 2015
- PAFSC 1st Committee to Discuss Actelion’s PAH Treatment on Feb. 20
February 9, 2015
- Panel OKs Intractable Disease Designation of Muscular Dystrophy
February 6, 2015
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…